Welcome to our dedicated page for Aim Immunotech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on Aim Immunotech stock.
AIM ImmunoTech Inc. develops immuno-pharma therapeutics led by Ampligen (rintatolimod), a dsRNA and selective TLR3 agonist immuno-modulator under development for late-stage pancreatic cancer and other cancer, viral disease and immune-disorder indications. Company news commonly covers clinical disclosures for Ampligen, including pancreatic cancer studies with checkpoint inhibitors, intellectual-property approvals, and regulatory designations.
Updates also address financing and capital-structure actions, such as rights offerings, preferred stock and warrant terms, at-the-market equity arrangements, shareholder voting matters, governance disclosures, operating results, and public-company reporting matters including audit and going-concern disclosures.
AIM ImmunoTech will participate in the Virtual Investor Pitch Conference on June 17, 2024, at 1:00 PM ET. CEO Thomas K. Equels will deliver an elevator pitch outlining the company's upcoming milestones. Investors can submit questions live during the event, with responses provided within the time constraints. The live video webcast will be available on AIM ImmunoTech's website, with a replay accessible for 90 days.
AIM ImmunoTech (NYSE American: AIM) announced that CEO Thomas K. Equels will participate in the Virtual Investor Lunch Break Series on June 5, 2024, at 12:00 PM ET. During the event, Mr. Equels will give a corporate overview and discuss the company's business outlook. Attendees can submit questions live, which Mr. Equels will address. The live webcast will be available on the company’s website, and a replay will be accessible for 90 days two hours after the presentation.
AIM ImmunoTech announced a $2 million registered direct offering with a single institutional investor. The deal includes the purchase of 5,640,958 shares of common stock at $0.363 per share and unregistered Class A and Class B warrants to buy an additional 5,640,958 shares each. The Class A warrants expire 18 months from issuance, while Class B warrants expire in five years. Maxim Group acts as the sole placement agent. The gross proceeds are around $2 million before fees and expenses. The offering is made under a shelf registration statement effective since February 4, 2022.
AIM ImmunoTech announced that its CEO, Thomas K. Equels, will participate in two upcoming investor conferences. The first event, the Healthcare Company Showcase hosted by Alliance Global Partners, will take place on May 21, 2024, at 3:20 PM ET. The second event, LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar, is scheduled for May 22, 2024, at 3:40 PM ET. Both presentations will be webcast live and accessible via the Events page on AIM ImmunoTech's Investor section of their website.
AIM ImmunoTech reported its Q1 2024 financial results, showing a net loss of $5.8 million, or $0.12 per share, compared to $3.7 million, or $0.08 per share, in Q1 2023. Cash reserves are at $10.9 million. The company highlighted progress in its Ampligen clinical programs, including positive interim data in ovarian cancer and the completion of cGMP manufacturing of 9,000 vials. AIM also announced that the first dose in a Phase 1b/2 study for late-stage pancreatic cancer was well-tolerated. Upcoming milestones include final data for Post-COVID Conditions in Q2 2024. AIM will host a conference call today, May 16, 2024, to discuss these results.
AIM ImmunoTech Inc. will hold a conference call and webcast on May 16, 2024, to discuss Q1 2024 operational and financial results. The call will be led by CEO Thomas K. Equels and Scientific Officer Christopher McAleer. Participants can join via phone or webcast on the aimimmuno.com website.
AIM ImmunoTech Inc. has completed cGMP manufacturing of 9,042 clinical vials of Ampligen® (rintatolimod), a dsRNA product candidate for cancer, viral diseases, and immune disorders. CEO Thomas K. Equels emphasized the importance of this milestone for the company's development and commercial strategies, highlighting ongoing clinical trials for solid tumors.
AIM ImmunoTech Inc. announced positive results in testing Ampligen and Imfinzi in late-stage pancreatic cancer treatment. The combination was well-tolerated with no severe adverse events. The next safety cohort will start escalated dosing soon. Subjects will be monitored for response for up to 48 weeks.
Summary not available.
Summary not available.